Letter: Real-World Japanese Study of the Effectiveness and Safety of Switching From Dupilumab to Lebrikizumab in Patients with Moderate to Severe Atopic Dermatitis

Dermatitis. 2026 Mar-Apr;37(2):e293-e295. doi: 10.1089/derm.2025.0046. Epub 2025 Apr 9.

Authors

Teppei Hagino¹, Akihiko Uchiyama², Marina Onda¹, Keiji Kosaka², Takeshi Araki², Sei-Ichiro Motegi², Hidehisa Saeki³, Eita Fujimoto⁴, Naoko Kanda¹

Affiliations

¹ Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
² Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
³ Department of Dermatology, Nippon Medical School, Tokyo, Japan.
⁴ Fujimoto Dermatology Clinic, Funabashi, Japan.

PMID: 40202458
DOI: 10.1089/derm.2025.0046

No abstract available

Publication types

Letter